following an abbreviated submission:
leuprorelin acetate (Prostap®) is accepted for use within NHSScotland.
Indication under review: as treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.
Leuprorelin offers an additional treatment choice in the therapeutic class of gonadotropin-releasing hormone (GnRH) analogues for this indication.
Download detailed advice722KB (PDF)
- Medicine name:
- leuprorelin acetate (Prostap DCS)
- SMC ID:
As treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 08 February 2021